The whole map. Five lanes, one left turn.

In the box: Retatrutide · GHK-Cu · MOTS-c · CJC-1295 (no DAC) + Ipamorelin · Wolverine (BPC-157 + TB-500).

Research use: studied as a cross-class panel — incretin/glucagon signaling beside tissue-repair peptides and a pulsed GHRH/GHRP pair. For labs comparing metabolic, mitochondrial, and repair literature in one procurement set instead of five separate orders. Not a protocol.

A small longevity three. The long way.

In the box: GHK-Cu · Epithalon · MOTS-c.

Research use: a compact longevity-class set — tetrapeptide telomerase literature, a mitochondrial-derived peptide, and a copper-binding tripeptide. Used in cellular-aging and extracellular-matrix models that want both a mitochondrial lane and a copper-peptide lane. Small on purpose. Not a treatment.

Small repair three. After the map opens.

In the box: Wolverine (BPC-157 + TB-500) · MOTS-c · CJC-1295 (no DAC) / Ipamorelin.

Research use: a compact repair-plus-pulse set — gastric-derived and thymosin-β4 analogs with a GHRH/GHRP pair. Studied in tissue-repair models that also want a physiological GH-pulse analog and a mitochondrial-derived peptide. Three items, three mechanisms, one bench. Not a healing protocol.

Two tracks. Metabolic and repair, side by side.

In the box: Retatrutide - GLOW (BPC-157 + GHK-Cu + TB-500).

Research use: a two-track design - a triple incretin/glucagon agonist beside a three-peptide repair/matrix blend. For labs running GLP-class work and tissue-repair peptides in parallel without buying five singles. GLOW is a catalog blend name, not a claim.

Narrow lane. Gut, mucosal, immune literature.

In the box: BPC-157 - KPV - Thymosin Alpha-1.

Research use: a narrow set for gastric-derived peptide, alpha-MSH fragment, and thymic immunomodulatory literature. Used in mucosal and inflammatory-signaling models that do not need a metabolic compound. Not a gut-health program.

Metabolic class only. Three compounds, open road.

In the box: AOD-9604 - Tesamorelin - Retatrutide.

Research use: a metabolic-class trio - a triple incretin/glucagon agonist, a GHRH analog used in visceral-adipose literature, and an hGH 176-191 fragment. Used in adipose-signaling and GH-axis models that want fragment, secretagogue, and incretin lanes in one order. Not a fat-loss program.

The long wellness bench. Eight research lanes.

In the box: Retatrutide - Cagrilintide - BPC-157 - KLOW (BPC-157 + GHK-Cu + TB-500 + KPV) - NAD+ - MOTS-c - Epithalon - 5-Amino-1MQ.

Research use: a broad wellness-class research set - GLP/amylin signaling, a four-peptide repair blend, NAD biochemistry, and longevity-associated peptides. Used by programs that procure metabolic, repair, and cellular-energy compounds in one lot rather than eight separate orders. It is a catalog of lanes, not a schedule. Not a wellness protocol.

Recovery-first. The wide stop, not the small three.

In the box: Tirzepatide - Cagrilintide - BPC-157 - TB-500 - GHK-Cu - DSIP - SS-31 - NAD+.

Research use: a recovery-class procurement set - dual incretin, an amylin analog, three repair peptides as singles, a sleep-associated peptide, a mitochondrial-targeted peptide, and NAD+. Used in tissue-repair and cellular-energy models that also want metabolic-class compounds in the same order. Repair peptides ship as singles so a lab can aliquot by assay. Not a recovery protocol.

Horizon kit. Further than the small three.

In the box: Retatrutide - BPC-157 - TB-500 - GHK-Cu - DSIP - NAD+ - MOTS-c.

Research use: a horizon-class set - a metabolic agonist, three repair singles, a sleep-associated peptide, NAD+, and a mitochondrial-derived peptide. Used by programs that want a broader aging-associated bench than Epithalon, MOTS-c, and GHK-Cu alone, where the design is cellular-energy plus matrix. Horizon is a direction, not a claim. Not an anti-aging treatment.